New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 19, 2012
15:44 EDTSNYSanofi to pay $109M to resolve allegations of physician kickbacks
Sanofi-Aventis U.S. Inc. and Sanofi-Aventis U.S. LLC, subsidiaries of international drug manufacturer Sanofi, have agreed to pay $109M to resolve allegations that Sanofi US violated the False Claims Act by giving physicians free units of Hyalgan, a knee injection, in violation of the Anti-Kickback Statute, to induce them to purchase and prescribe the product. The settlement also resolves allegations that Sanofi US submitted false average sales price (ASP) reports for Hyalgan that failed to account for free units distributed contingent on Hyalgan purchases. The government alleges that the false ASP reports, which were used to set reimbursement rates, caused government programs to pay inflated amounts for Hyalgan and a competing product. Reference Link
News For SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 29, 2015
19:37 EDTSNYSanofi working with Lazard to explore sale of animal health unit, Reuters says
Lazard (LAZ) is working with Sanofi (SNY) to prepare a sale or listing of the company's Merial animal health division, which could value the unit at up to $12.7B, reports Reuters, citing sources. The investment bank is expected to land the lead advisory role for the potential deal, sources told Reuters, which added that the sale would play a "pivotal role" in getting Sanofi "back on track." Reference Link
November 24, 2015
05:23 EDTSNYSanofi, Regeneron announce Praluent ODYSSEY OUTCOMES trial enrollment complete
Subscribe for More Information
November 20, 2015
06:09 EDTSNYSanofi, AstraZeneca to exchange more than 210,000 compounds
Subscribe for More Information
November 18, 2015
08:11 EDTSNYIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use